Skip to content

Study · Randomized controlled trial · n = 17 · 2000

4 results

Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.

Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A

Journal of pain and symptom management1 Jan 2000Cited by 117 (Europe PMC)

PMID10687323 (opens in a new tab)DOI10.1016/s0885-3924(99)00147-5 (opens in a new tab)PepBankPUB-10687323
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with inoperable malignant bowel obstruction, daily thirst intensity did not differ between octreotide and scopolamine butylbromide.

    In plain wordsIn patients with inoperable malignant bowel obstruction, daily thirst did not differ between octreotide and scopolamine butylbromide.

    Peptide
    Octreotide
    Outcome
    No significant changeDaily thirst intensity
    Study

    n = 17

    Comparator
    Scopolamine butylbromide
    Outcome group
    Appetite and food intake · Gastrointestinal
    Studied dose
    0.3 mg/day · continuous subcutaneous infusion · 3 daysAs given in this study (human).

    Source sentences

    Summary
    There was no difference in the daily thirst and dry mouth intensity in relation to the amount of parenteral hydration or the treatment provided (OCT or SB).
    1 context sentence
    Summary · context
    In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a continuous subcutaneous infusion.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with inoperable malignant bowel obstruction, daily dry mouth intensity did not differ between octreotide and scopolamine butylbromide.

    In plain wordsIn patients with inoperable malignant bowel obstruction, dry mouth did not differ between octreotide and scopolamine butylbromide.

    Peptide
    Octreotide
    Outcome
    No significant changeDaily dry mouth intensity
    Study

    n = 17

    Comparator
    Scopolamine butylbromide
    Outcome group
    Dry mouth · Gastrointestinal
    Studied dose
    0.3 mg/day · continuous subcutaneous infusion · 3 daysAs given in this study (human).

    Source sentences

    Summary
    There was no difference in the daily thirst and dry mouth intensity in relation to the amount of parenteral hydration or the treatment provided (OCT or SB).
    1 context sentence
    Summary · context
    In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a continuous subcutaneous infusion.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with inoperable malignant bowel obstruction, octreotide significantly reduced gastrointestinal secretions at T2 (P = 0.016); the reference was not stated.

    In plain wordsIn patients with inoperable malignant bowel obstruction, octreotide reduced gut secretions at T2; the result does not name a reference.

    Peptide
    Octreotide
    Outcome
    DecreaseGastrointestinal secretions at T2
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg/day · continuous subcutaneous infusion · 3 daysAs given in this study (human).

    Source sentences

    Summary
    OCT significantly reduced the amount of GI secretions at T2 (P = 0.016) and T3 (P = 0.020).
    1 context sentence
    Summary · context
    In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a continuous subcutaneous infusion.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with inoperable malignant bowel obstruction, octreotide significantly reduced gastrointestinal secretions at T3 (P = 0.020); the reference was not stated.

    In plain wordsIn patients with inoperable malignant bowel obstruction, octreotide reduced gut secretions at T3; the result does not name a reference.

    Peptide
    Octreotide
    Outcome
    DecreaseGastrointestinal secretions at T3
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg/day · continuous subcutaneous infusion · 3 daysAs given in this study (human).

    Source sentences

    Summary
    OCT significantly reduced the amount of GI secretions at T2 (P = 0.016) and T3 (P = 0.020).
    1 context sentence
    Summary · context
    In a prospective trial that involved all 17 inoperable bowel-obstructed patients presenting to our services with a decompressive NGT, patients were randomized to OCT 0.3 mg/day or SB 60 mg/day for 3 days through a continuous subcutaneous infusion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.